A little more than a year ago, GlaxoSmithKline disbanded George Vlasuk's team at Sirtris and absorbed the R&D work in its Pennsylvania operations. But that didn't end the relationship. Today Vlasuk is back at the helm of a new biotech dubbed Navitor Pharmaceuticals, which was seeded initially by Polaris and is now coming out of stealth mode with a $23.5 million Series A and the backing of a syndicate that includes SR One, GlaxoSmithKline's venture arm.
Two months removed from a deal that sent her last biotech to Bristol-Myers Squibb for up to $725 million, CEO Nancy Stagliano isn't wasting any time, setting sights on rare diseases with True North Therapeutics, her latest venture, and locking down a $22 million A round to move forward.
Biotech Seres Health has raised a quick $10 million B round to support its work in microbiome R&D, appending a partnership with the Mayo Clinic as it advances an infectious disease treatment.
Two biotech startups have hauled in a combined $38 million in Series B funding, pledging to advance their programs in inflammation and skin disease.
Having backed biotech IT businesses like Comprehend Systems and SV Bio in the U.S., high-profile venture firm Sequoia Capital has turned its attention to India. And with a $530 million fund to fuel its ambitions, the California-based VC shop could kick-start the tech and healthcare startup ecosystem in India and across Southeast Asia.
Armed with ex-Merck immunotherapy and some promising preclinical data, startup ARMO BioSciences has pulled in $30 million in venture cash to study whether its candidate can help kill cancer cells by galvanizing an immune system response.
Eli Lilly has taken the unusual step of investing in Epidarex Capital's new, $80 million life sciences fund, with an eye to backing the Scotland-based group's portfolio of academic spinouts. This was Lilly's first investment in a U.K. venture fund.
About a year after launching with the help of Atlas Venture and Johnson & Johnson's Massachusetts biotech incubator, Cambridge's Rodin Therapeutics is setting out with $12.9 million in Series A cash and a plan to apply some cutting-edge science to common central nervous system disorders.
After seeding a fledgling scientific effort focused on the biologic implications of regulating proteins, Third Rock and The Column Group are throwing $25 million behind a startup biotech--Nurix--that hopes to blaze a new path in small molecule drug development.
You can add another upstart to the swelling list of gene therapy biotechs hitting the industry radar around the world. Sofinnova stepped in to lead the $22 million A round for Paris-based Lysogene, which is already in the clinic with a new therapy for rare cases of Sanfilippo syndrome, with plans to branch out into other neurodegenerative conditions.